Ventyx Biosciences, Inc. (VTYX)

2.5100 0.0000 (0.00%) At close: 04:00PM EDT

Ventyx Biosciences, Inc.

12790 El Camino Real
Suite 200
San Diego, CA 92130
United States
760 593 4832
https://ventyxbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 74

Description

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Corporate governance

Ventyx Biosciences, Inc.’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.